Table 2
Recurrence in Controlled Comparison Trials
|
Study/References |
BCG |
Thiotepa |
Doxorubicin |
Mitomycin C |
P Level |
|
Brosman |
0 |
47% |
|
|
<0.01 |
|
Rodriques Netto and Lemos |
7% |
43% |
|
|
<0.01 |
|
Martinez-Pineiro et al |
17% |
36% |
43% |
|
<0.01 |
|
BCG/Thiotepa Average |
7% |
42% |
|
|
|
|
Lamm et al |
63% |
|
83% |
|
<0.02 |
|
BCG/Doxorubicin Average |
38% |
|
63% |
|
|
|
Debruyne et al |
30% |
|
|
25% |
NS |
|
Juahianen et al |
288% |
|
|
62% |
<-0.01 |
|
Rubben et al |
35% |
|
|
35% |
NS |
|
Witjes et al |
29% (RIVM) |
|
|
26% |
NS |
|
|
34% (TICE) |
|
|
|
NS |
|
Lamm et al |
20% |
|
|
33% |
<0.01 |
|
BCG/Mitomycin Average |
29% |
|
|
36% |
|
|
BCG Average |
25% |
|
|
|
|
|
Chemotherapy Average |
43% |
|
|
|
|
KEY: BCG = bacillus Calmette-Guerin